Fundacion Instituto Valenciano de Oncología
Welcome,         Profile    Billing    Logout  
 0 Trials 
55 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sponsor, Principal investigator Selected by
PROTINCOL, NCT05625932 / 2022-001534-11: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Recruiting
3
526
Europe
Tinzaparin, Innohep
Galician Research Group on Digestive Tumors, LEO Pharma
Colorectal Cancer Metastatic, Thromboembolism
12/24
03/25
RIALTO, NCT06878664: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Not yet recruiting
3
166
Europe
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE, LUTATHERA, lutetium (177Lu) oxodotreotide, 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution, Lanreotide (Autogel formulation) or Octreotide LAR
Grupo Espanol de Tumores Neuroendocrinos, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
01/29
01/29
EBRAIN-MEL, NCT03898908 / 2018-002530-20: Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

Active, not recruiting
2
48
Europe
encorafenib, Braftovi, binimetinib, Mektovi, Whole brain radiation therapy, Radiosurgery/stereotactic radiosurgery
Grupo Español Multidisciplinar de Melanoma, Pierre Fabre Medicament, MFAR
Metastatic Melanoma, Brain Metastases
10/22
10/23
GETNE-T1913, NCT03980925 / 2019-001546-18: Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Completed
2
37
Europe
Nivolumab, Carboplatin, Etoposide
Grupo Espanol de Tumores Neuroendocrinos
Neuroendocrine Tumors, Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Tumor
02/23
06/23
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial

Terminated
2
79
Europe
Durvalumab, MEDI4736, Tremelimumab
Grupo Espanol de Tumores Neuroendocrinos, MFAR
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
11/24
11/24
CABATEN, NCT04400474: Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The Study

Active, not recruiting
2
93
Europe
Cabozantinib 40 mg, Atezolizumab 1200 mg
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, Roche Pharma AG
Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma
12/23
03/24
LIVERPEARL, NCT04595266: Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease

Recruiting
2
48
Europe
FOLFOX regimen, Leucovorin/Fluorouracil/Oxaliplatin, Anti-EGFR or Bevacizumab, monoclonal antibody anti EGFR (RASwt) or Bevacizumab (RASmut), LIVERPEARLS-Irinotecan, Chemoembolization of Irinotecan in hydrogel microspheres
Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer
01/24
01/25
SITISVEAL, NCT05542342 / 2021-002474-99: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

Active, not recruiting
2
16
Europe
Tislelizumab, Sitravatinib Malate
Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene
Uveal Melanoma
12/23
08/25
NCT06538857: CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting
2
21
Europe
Standard surgery, CEB-01
CEBIOTEX, MFAR
Pancreatic Carcinoma
09/28
09/28
PEMBROLA, NCT05201612: Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Recruiting
2
40
Europe
Olaparib, Lynparza, Pembrolizumab, Keytruda
Grupo Espanol Multidisciplinario del Cancer Digestivo, Merk Sharp & Dohme España S.A.
Metastatic Colorectal Cancer
09/24
03/25
VEXILLUM, NCT05219435 / 2021-005364-22: Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Recruiting
2
66
Europe
Nivolumab, Opdivo, Ipilimumab, Yervoy
Spanish Oncology Genito-Urinary Group, Bristol-Myers Squibb
Urothelial Cancer
03/25
12/25
ERBIOTAX, NCT06856213: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Not yet recruiting
2
65
Europe
Cetuximab, Paclitaxel
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
10/28
10/28
PlugIN, NCT06906822: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Not yet recruiting
2
60
Europe
enfortumab vedotin, pembrolizumab
Grupo Español Multidisciplinar de Melanoma, Merck Sharp & Dohme LLC, Astellas Pharma Inc
Melanoma
04/25
04/25
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Not yet recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
CABOTHYROID, NCT05660954: Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting
2
41
Europe
Cabozantinib
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR
Differentiated Thyroid Cancer
06/25
06/25
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
VENEZO-LUNG, NCT04487756: Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

Active, not recruiting
1/2
20
Europe
Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, ADC Vaccine, Autologous Dendritic cell (ADC) vaccine, Dendritic cell (DC) vaccine, Carboplatin, Carboplatino (Teva/Accord/Pharmacia)
Instituto Oncológico Dr Rosell, Roche Pharma AG, Fundacion Clinic per a la Recerca Biomédica
Extensive-stage Small Cell Lung Cancer
08/24
10/24
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
AFAN, NCT06648096: Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
1/2
25
Europe
Afatinib
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, MFAR Clinical Research S.L.
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
12/28
12/28
GEINOCANN, NCT03529448: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

Active, not recruiting
1/2
33
Europe
TN-TC11G, Temozolomide Oral Product, Temozolomide, Radiotherapy, STUPP
Grupo Español de Investigación en Neurooncología, Medical Cannabis Bike Tour, Voices Against Brain Cancer, Tilray
Glioblastoma
03/25
12/25
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Active, not recruiting
1
21
Europe
CEB-01 membrane loaded with SN-38
CEBIOTEX
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
05/25
05/25
TOTEM, NCT04772235: Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients

Recruiting
1
32
Europe
Repotrectinib, TPX-0005, Osimertinib, Tagrisso
Instituto Oncológico Dr Rosell, Turning Point Therapeutics, Inc.
Nsclc
04/26
06/26
NUTRIGETNE, NCT04986085: Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Completed
N/A
399
Europe
Grupo Espanol de Tumores Neuroendocrinos
Gastroenteropancreatic Neuroendocrine Tumor
01/24
02/24
REGETNE-Tiroides, NCT03765333: GETNE Registration of Thyroid Cancer

Recruiting
N/A
20
Europe
Grupo Espanol de Tumores Neuroendocrinos
Thyroid Cancer
12/25
12/25
TESEO, NCT03855592: Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

Recruiting
N/A
700
Europe
Fundación Sociedad Española de Oncologia Médica
Thromboembolism, Cancer
07/24
07/24
REVEAL, NCT05674422: GEMCAD- STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.

Active, not recruiting
N/A
120
Europe
total neoadjuvant therapy
Grupo Espanol Multidisciplinario del Cancer Digestivo
Patients With Locally Advanced Rectal Cancer
04/25
07/26
GEM-1801, NCT03605771: Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

Recruiting
N/A
400
Europe
Daily Clinical Practice
Grupo Español Multidisciplinar de Melanoma
Melanoma Stage Iv, Melanoma Stage Iii, Advanced Cancer
12/25
12/25
SPAINTRK, NCT06837090: Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain

Recruiting
N/A
19
Europe
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Solid Neoplasms With NTRK Fusions
12/25
01/26
Sponsor, A responsible person Designated by the
PROTINCOL, NCT05625932 / 2022-001534-11: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Recruiting
3
526
Europe
Tinzaparin, Innohep
Galician Research Group on Digestive Tumors, LEO Pharma
Colorectal Cancer Metastatic, Thromboembolism
12/24
03/25
RIALTO, NCT06878664: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Not yet recruiting
3
166
Europe
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE, LUTATHERA, lutetium (177Lu) oxodotreotide, 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution, Lanreotide (Autogel formulation) or Octreotide LAR
Grupo Espanol de Tumores Neuroendocrinos, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
01/29
01/29
LEVEL, NCT05918302: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Recruiting
3
120
Europe
177Lu-edotreotide, Everolimus
Grupo Espanol de Tumores Neuroendocrinos, ITM Oncologics GmbH, MFAR
Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
03/28
07/28
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial

Terminated
2
79
Europe
Durvalumab, MEDI4736, Tremelimumab
Grupo Espanol de Tumores Neuroendocrinos, MFAR
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
11/24
11/24
SITISVEAL, NCT05542342 / 2021-002474-99: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

Active, not recruiting
2
16
Europe
Tislelizumab, Sitravatinib Malate
Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene
Uveal Melanoma
12/23
08/25
NCT06538857: CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting
2
21
Europe
Standard surgery, CEB-01
CEBIOTEX, MFAR
Pancreatic Carcinoma
09/28
09/28
PEMBROLA, NCT05201612: Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Recruiting
2
40
Europe
Olaparib, Lynparza, Pembrolizumab, Keytruda
Grupo Espanol Multidisciplinario del Cancer Digestivo, Merk Sharp & Dohme España S.A.
Metastatic Colorectal Cancer
09/24
03/25
SETHY, NCT06235216: Sacituzumab govitEcan in THYroid Cancers

Recruiting
2
42
Europe
Sacituzumab govitecan, Trodelvy
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Gilead Sciences
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
12/27
12/27
VERDI, NCT06668558: Venetoclax + Azacitidine in Patients with Acute Myeloid Leukemia

Not yet recruiting
2
29
Europe
Azacitidine (AZA), Venetoclax
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Acute Myeloid Leukemia
06/28
07/28
VEXILLUM, NCT05219435 / 2021-005364-22: Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Recruiting
2
66
Europe
Nivolumab, Opdivo, Ipilimumab, Yervoy
Spanish Oncology Genito-Urinary Group, Bristol-Myers Squibb
Urothelial Cancer
03/25
12/25
ERBIOTAX, NCT06856213: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Not yet recruiting
2
65
Europe
Cetuximab, Paclitaxel
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
10/28
10/28
PlugIN, NCT06906822: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Not yet recruiting
2
60
Europe
enfortumab vedotin, pembrolizumab
Grupo Español Multidisciplinar de Melanoma, Merck Sharp & Dohme LLC, Astellas Pharma Inc
Melanoma
04/25
04/25
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Not yet recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
CABOTHYROID, NCT05660954: Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting
2
41
Europe
Cabozantinib
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR
Differentiated Thyroid Cancer
06/25
06/25
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
AFAN, NCT06648096: Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
1/2
25
Europe
Afatinib
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, MFAR Clinical Research S.L.
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
12/28
12/28
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Active, not recruiting
1
21
Europe
CEB-01 membrane loaded with SN-38
CEBIOTEX
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
05/25
05/25
MOLTHY, NCT04970134: Spanish Study for Molecular Characterization of Thyroid Carcinoma

Active, not recruiting
N/A
150
Europe
Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Oncomine Focus Assay Platform with 52 genes, Next Generation Sequencing (NGS)
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Differentiated Thyroid Carcinoma, Medullary Thyroid Carcinoma
01/23
03/25
NUTRIGETNE, NCT04986085: Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Completed
N/A
399
Europe
Grupo Espanol de Tumores Neuroendocrinos
Gastroenteropancreatic Neuroendocrine Tumor
01/24
02/24
REGETNE-Tiroides, NCT03765333: GETNE Registration of Thyroid Cancer

Recruiting
N/A
20
Europe
Grupo Espanol de Tumores Neuroendocrinos
Thyroid Cancer
12/25
12/25
TESEO, NCT03855592: Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

Recruiting
N/A
700
Europe
Fundación Sociedad Española de Oncologia Médica
Thromboembolism, Cancer
07/24
07/24
SOGUG-PRINCIS, NCT06724159: Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

Recruiting
N/A
500
Europe
darolutamide, Nivolumab monotherapy, enfortumab vedotin
Spanish Oncology Genito-Urinary Group, MFAR
Genitourinary Cancers
12/27
12/27
SPAINTRK, NCT06837090: Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain

Recruiting
N/A
19
Europe
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Solid Neoplasms With NTRK Fusions
12/25
01/26
REPTT, NCT05914441: Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

Recruiting
N/A
300
Europe
Standard clinical practice
Fundación Española de Hematología y Hemoterapía
Purpura, Thrombocytopenic
09/26
12/26
Sosa, Marcos Melian
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Recruiting
3
733
Europe, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred
Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
07/29
07/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sponsor, Principal investigator Selected by
PROTINCOL, NCT05625932 / 2022-001534-11: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Recruiting
3
526
Europe
Tinzaparin, Innohep
Galician Research Group on Digestive Tumors, LEO Pharma
Colorectal Cancer Metastatic, Thromboembolism
12/24
03/25
RIALTO, NCT06878664: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Not yet recruiting
3
166
Europe
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE, LUTATHERA, lutetium (177Lu) oxodotreotide, 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution, Lanreotide (Autogel formulation) or Octreotide LAR
Grupo Espanol de Tumores Neuroendocrinos, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
01/29
01/29
EBRAIN-MEL, NCT03898908 / 2018-002530-20: Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

Active, not recruiting
2
48
Europe
encorafenib, Braftovi, binimetinib, Mektovi, Whole brain radiation therapy, Radiosurgery/stereotactic radiosurgery
Grupo Español Multidisciplinar de Melanoma, Pierre Fabre Medicament, MFAR
Metastatic Melanoma, Brain Metastases
10/22
10/23
GETNE-T1913, NCT03980925 / 2019-001546-18: Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Completed
2
37
Europe
Nivolumab, Carboplatin, Etoposide
Grupo Espanol de Tumores Neuroendocrinos
Neuroendocrine Tumors, Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Tumor
02/23
06/23
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial

Terminated
2
79
Europe
Durvalumab, MEDI4736, Tremelimumab
Grupo Espanol de Tumores Neuroendocrinos, MFAR
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
11/24
11/24
CABATEN, NCT04400474: Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The Study

Active, not recruiting
2
93
Europe
Cabozantinib 40 mg, Atezolizumab 1200 mg
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, Roche Pharma AG
Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma
12/23
03/24
LIVERPEARL, NCT04595266: Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease

Recruiting
2
48
Europe
FOLFOX regimen, Leucovorin/Fluorouracil/Oxaliplatin, Anti-EGFR or Bevacizumab, monoclonal antibody anti EGFR (RASwt) or Bevacizumab (RASmut), LIVERPEARLS-Irinotecan, Chemoembolization of Irinotecan in hydrogel microspheres
Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer
01/24
01/25
SITISVEAL, NCT05542342 / 2021-002474-99: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

Active, not recruiting
2
16
Europe
Tislelizumab, Sitravatinib Malate
Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene
Uveal Melanoma
12/23
08/25
NCT06538857: CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting
2
21
Europe
Standard surgery, CEB-01
CEBIOTEX, MFAR
Pancreatic Carcinoma
09/28
09/28
PEMBROLA, NCT05201612: Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Recruiting
2
40
Europe
Olaparib, Lynparza, Pembrolizumab, Keytruda
Grupo Espanol Multidisciplinario del Cancer Digestivo, Merk Sharp & Dohme España S.A.
Metastatic Colorectal Cancer
09/24
03/25
VEXILLUM, NCT05219435 / 2021-005364-22: Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Recruiting
2
66
Europe
Nivolumab, Opdivo, Ipilimumab, Yervoy
Spanish Oncology Genito-Urinary Group, Bristol-Myers Squibb
Urothelial Cancer
03/25
12/25
ERBIOTAX, NCT06856213: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Not yet recruiting
2
65
Europe
Cetuximab, Paclitaxel
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
10/28
10/28
PlugIN, NCT06906822: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Not yet recruiting
2
60
Europe
enfortumab vedotin, pembrolizumab
Grupo Español Multidisciplinar de Melanoma, Merck Sharp & Dohme LLC, Astellas Pharma Inc
Melanoma
04/25
04/25
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Not yet recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
CABOTHYROID, NCT05660954: Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting
2
41
Europe
Cabozantinib
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR
Differentiated Thyroid Cancer
06/25
06/25
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
VENEZO-LUNG, NCT04487756: Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

Active, not recruiting
1/2
20
Europe
Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, ADC Vaccine, Autologous Dendritic cell (ADC) vaccine, Dendritic cell (DC) vaccine, Carboplatin, Carboplatino (Teva/Accord/Pharmacia)
Instituto Oncológico Dr Rosell, Roche Pharma AG, Fundacion Clinic per a la Recerca Biomédica
Extensive-stage Small Cell Lung Cancer
08/24
10/24
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
AFAN, NCT06648096: Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
1/2
25
Europe
Afatinib
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, MFAR Clinical Research S.L.
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
12/28
12/28
GEINOCANN, NCT03529448: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

Active, not recruiting
1/2
33
Europe
TN-TC11G, Temozolomide Oral Product, Temozolomide, Radiotherapy, STUPP
Grupo Español de Investigación en Neurooncología, Medical Cannabis Bike Tour, Voices Against Brain Cancer, Tilray
Glioblastoma
03/25
12/25
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Active, not recruiting
1
21
Europe
CEB-01 membrane loaded with SN-38
CEBIOTEX
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
05/25
05/25
TOTEM, NCT04772235: Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients

Recruiting
1
32
Europe
Repotrectinib, TPX-0005, Osimertinib, Tagrisso
Instituto Oncológico Dr Rosell, Turning Point Therapeutics, Inc.
Nsclc
04/26
06/26
NUTRIGETNE, NCT04986085: Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Completed
N/A
399
Europe
Grupo Espanol de Tumores Neuroendocrinos
Gastroenteropancreatic Neuroendocrine Tumor
01/24
02/24
REGETNE-Tiroides, NCT03765333: GETNE Registration of Thyroid Cancer

Recruiting
N/A
20
Europe
Grupo Espanol de Tumores Neuroendocrinos
Thyroid Cancer
12/25
12/25
TESEO, NCT03855592: Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

Recruiting
N/A
700
Europe
Fundación Sociedad Española de Oncologia Médica
Thromboembolism, Cancer
07/24
07/24
REVEAL, NCT05674422: GEMCAD- STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.

Active, not recruiting
N/A
120
Europe
total neoadjuvant therapy
Grupo Espanol Multidisciplinario del Cancer Digestivo
Patients With Locally Advanced Rectal Cancer
04/25
07/26
GEM-1801, NCT03605771: Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

Recruiting
N/A
400
Europe
Daily Clinical Practice
Grupo Español Multidisciplinar de Melanoma
Melanoma Stage Iv, Melanoma Stage Iii, Advanced Cancer
12/25
12/25
SPAINTRK, NCT06837090: Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain

Recruiting
N/A
19
Europe
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Solid Neoplasms With NTRK Fusions
12/25
01/26
Sponsor, A responsible person Designated by the
PROTINCOL, NCT05625932 / 2022-001534-11: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Recruiting
3
526
Europe
Tinzaparin, Innohep
Galician Research Group on Digestive Tumors, LEO Pharma
Colorectal Cancer Metastatic, Thromboembolism
12/24
03/25
RIALTO, NCT06878664: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Not yet recruiting
3
166
Europe
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE, LUTATHERA, lutetium (177Lu) oxodotreotide, 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution, Lanreotide (Autogel formulation) or Octreotide LAR
Grupo Espanol de Tumores Neuroendocrinos, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
01/29
01/29
LEVEL, NCT05918302: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Recruiting
3
120
Europe
177Lu-edotreotide, Everolimus
Grupo Espanol de Tumores Neuroendocrinos, ITM Oncologics GmbH, MFAR
Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
03/28
07/28
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial

Terminated
2
79
Europe
Durvalumab, MEDI4736, Tremelimumab
Grupo Espanol de Tumores Neuroendocrinos, MFAR
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
11/24
11/24
SITISVEAL, NCT05542342 / 2021-002474-99: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

Active, not recruiting
2
16
Europe
Tislelizumab, Sitravatinib Malate
Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene
Uveal Melanoma
12/23
08/25
NCT06538857: CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting
2
21
Europe
Standard surgery, CEB-01
CEBIOTEX, MFAR
Pancreatic Carcinoma
09/28
09/28
PEMBROLA, NCT05201612: Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Recruiting
2
40
Europe
Olaparib, Lynparza, Pembrolizumab, Keytruda
Grupo Espanol Multidisciplinario del Cancer Digestivo, Merk Sharp & Dohme España S.A.
Metastatic Colorectal Cancer
09/24
03/25
SETHY, NCT06235216: Sacituzumab govitEcan in THYroid Cancers

Recruiting
2
42
Europe
Sacituzumab govitecan, Trodelvy
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Gilead Sciences
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
12/27
12/27
VERDI, NCT06668558: Venetoclax + Azacitidine in Patients with Acute Myeloid Leukemia

Not yet recruiting
2
29
Europe
Azacitidine (AZA), Venetoclax
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Acute Myeloid Leukemia
06/28
07/28
VEXILLUM, NCT05219435 / 2021-005364-22: Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Recruiting
2
66
Europe
Nivolumab, Opdivo, Ipilimumab, Yervoy
Spanish Oncology Genito-Urinary Group, Bristol-Myers Squibb
Urothelial Cancer
03/25
12/25
ERBIOTAX, NCT06856213: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Not yet recruiting
2
65
Europe
Cetuximab, Paclitaxel
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
10/28
10/28
PlugIN, NCT06906822: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Not yet recruiting
2
60
Europe
enfortumab vedotin, pembrolizumab
Grupo Español Multidisciplinar de Melanoma, Merck Sharp & Dohme LLC, Astellas Pharma Inc
Melanoma
04/25
04/25
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Not yet recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
CABOTHYROID, NCT05660954: Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting
2
41
Europe
Cabozantinib
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR
Differentiated Thyroid Cancer
06/25
06/25
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
AFAN, NCT06648096: Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
1/2
25
Europe
Afatinib
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, MFAR Clinical Research S.L.
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
12/28
12/28
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Active, not recruiting
1
21
Europe
CEB-01 membrane loaded with SN-38
CEBIOTEX
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
05/25
05/25
MOLTHY, NCT04970134: Spanish Study for Molecular Characterization of Thyroid Carcinoma

Active, not recruiting
N/A
150
Europe
Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Oncomine Focus Assay Platform with 52 genes, Next Generation Sequencing (NGS)
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Differentiated Thyroid Carcinoma, Medullary Thyroid Carcinoma
01/23
03/25
NUTRIGETNE, NCT04986085: Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Completed
N/A
399
Europe
Grupo Espanol de Tumores Neuroendocrinos
Gastroenteropancreatic Neuroendocrine Tumor
01/24
02/24
REGETNE-Tiroides, NCT03765333: GETNE Registration of Thyroid Cancer

Recruiting
N/A
20
Europe
Grupo Espanol de Tumores Neuroendocrinos
Thyroid Cancer
12/25
12/25
TESEO, NCT03855592: Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

Recruiting
N/A
700
Europe
Fundación Sociedad Española de Oncologia Médica
Thromboembolism, Cancer
07/24
07/24
SOGUG-PRINCIS, NCT06724159: Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

Recruiting
N/A
500
Europe
darolutamide, Nivolumab monotherapy, enfortumab vedotin
Spanish Oncology Genito-Urinary Group, MFAR
Genitourinary Cancers
12/27
12/27
SPAINTRK, NCT06837090: Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain

Recruiting
N/A
19
Europe
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Solid Neoplasms With NTRK Fusions
12/25
01/26
REPTT, NCT05914441: Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

Recruiting
N/A
300
Europe
Standard clinical practice
Fundación Española de Hematología y Hemoterapía
Purpura, Thrombocytopenic
09/26
12/26
Sosa, Marcos Melian
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Recruiting
3
733
Europe, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred
Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
07/29
07/29

Download Options